Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE: 600521)
Health Care · Pharmaceuticals · CN
CN¥16.34
+2.90% today · -22.2% 1Y
Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE: 600521) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.63B and employs 8,797 people.
Over the last twelve months the share price has lost 22.2%, trading between 13.73 and 21.55.
Tweenvest scores Zhejiang Huahai Pharmaceutical Co., Ltd. across four factors: quality 66/100, value 57/100, growth 28/100, dividend 31/100. Its strongest factor is quality.
600521 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.63B
- Revenue (TTM)
- $1.32B
- P/E
- 38.88
- EPS
- 0.42
- Dividend yield
- 0.61%
- Beta (5Y)
- 0.16
- 52-week high
- CN¥21.55
- 52-week low
- CN¥13.73
- Avg volume (3M)
- —
- Shares outstanding
- 1.49B
- Employees
- 8,797
- Next earnings
- —
About Zhejiang Huahai Pharmaceutical Co., Ltd.
Zhejiang Huahai Pharmaceutical Co., Ltd. is a China-based pharmaceutical enterprise with a global presence. Its diverse portfolio encompasses treatments for central nervous system disorders, cardiovascular conditions, and viral infections, among other finished pharmaceutical products. Beyond finished drugs, the company also produces Active Pharmaceutical Ingredients (APIs) and crucial intermediates. Huahai Pharmaceutical further engages in the manufacturing of packaging components, notably high-density polyethylene (HDPE) bottles and polypropylene (PP) caps. Additionally, it offers contract manufacturing (CMO) and other specialized services, while also playing a role in import and export trade services. Established in 1989, the company maintains its headquarters in Linhai, China.
- ISIN
- CNE000001DL5
- Founded
- 1989
- Listed since
- Mar 4, 2003
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Emcure Pharmaceuticals LimitedNSEI: EMCURE | $3.83B | Rs1,944.60 | -0.31% |
| Shijiazhuang Yiling Pharmaceutical Co., Ltd.SZSE: 002603 | $3.82B | CN¥15.35 | +1.39% |
| Hypera S.A.BOVESPA: HYPE3 | $3.75B | R$26.70 | -2.27% |
| Simcere Pharmaceutical Group LimitedSEHK: 2096 | $3.75B | HK$11.46 | +2.41% |
| Organon & Co.NYSE: OGN | $3.61B | $13.75 | -0.29% |
| Camurus AB (publ)OM: CAMX | $3.61B | Skr630.00 | +3.62% |
| Sam Chun Dang Pharm. Co., LtdKOSDAQ: A000250 | $3.60B | ₩207,000.00 | +24.92% |
| Hubei Jumpcan Pharmaceutical Co., Ltd.SHSE: 600566 | $3.58B | CN¥26.02 | +1.52% |
Figures last refreshed Oct 4, 2026.